|
| Primary information |
|---|
| ID | 10828 |
| Therapeutic ID | Th1194 |
| Protein Name | Tuberculin Purified Protein Derivative |
| Sequence | NA
|
| Molecular Weight | NA |
| Chemical Formula | NA |
| Isoelectric Point | NA |
| Hydrophobicity | NA |
| Melting point | NA |
| Half-life | NA |
| Description | Aplisol (tuberculin PPD, diluted) is a sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis. The solution is stabilized with polysorbate (Tween) 80, buffered with potassium and sodium phosphates and contains 0.25% phenol as a preservative. The purified protein fraction is isolated from culture media filtrates of a human strain of Mycobacterium tuberculosis. |
| Indication/Disease | Used in the detection of infection with Mycobacterium tuberculosis. |
| Pharmacodynamics | NA |
| Mechanism of Action | NA |
| Toxicity | Some adverse effects at the injection site include pain, discomfort, pyrexia, and erythema, rash, hemorrhage, hematoma and rarely ulcer and necrosis. Other unwanted effects include severe hypersensitivity reactions, dyspnea, generalized rash and syncope. |
| Metabolism | NA |
| Absorption | NA |
| NA |
| Clearance | NA |
| Categories | Antigens,Antigens, Bacterial,Antihistamine Drugs,Biological Factors,Cell-mediated Immunity,Compounds used in a research, industrial, or household setting,Indicators and Reagents,Laboratory Chemicals,Skin Test Antigen,Tuberculin,Tuberculosis,Tuberculosis Skin Test |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | NA |
| Target | Toll-like receptor 2 |
| Brand Name | Aplisol |
| Company | Par Pharmaceutical, Inc. |
| Brand Description | Par Pharmaceutical, Inc. |
| Prescribed For | Detecting tuberculosis (TB) infection. |
| Chemical Name | NA |
| Formulation | The solution is stabilized with polysorbate (Tween) 80, buffered with potassium and sodium phosphates and contains approximately 0.35% phenol as a preservative. |
| Physical Appearance | solution for injection |
| Route of Administration | intradermal |
| Recommended Dosage | Diagnosis: Mantoux test, inject 0.1 mL (5 tuberculin units) intradermally; the result is read 48 to 72 hours after administration |
| Contraindication | Previous positive tuberculin skin test responsiveness suppressed within 6 weeks of viral infection, inactive TB, immunosuppression, geriatric |
| Side Effects | Commonside effect include Pain, itching, or redness at the injection site. Sever side effect mmay occur Severe allergic reactions (rash; hives; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); blisters; open sores. |
| Useful Link 1 | Link |
| Useful Link 2 | NA |
| Remarks | NA |